*--adds broker comment--*
ECO Animal Health (LON:EAH) has received first approval for its antibiotic Aivlosin in another key market as the South Korean authorities gave it the green light.
The marketing authorisation is for the use of a 42.5 mg/g premix and will be marketed for the treatment of diseases caused by Mycoplasma hyopneumoniae, one of the most important contributors to respiratory diseases in pigs.
A long standing relationship with a South Korean distributor had assisted in obtaining the marketing authorisation, said ECO.
Launch plans for Aivlosin in Korea are well advanced and is expected to take place within a couple of months, it said.
Pork is only second in importance to rice in South Korean agriculture with almost one million metric tons produced every year, with consumption increasing faster than any other type of meat.
Peter Lawrence, ECO Animal’s chairman said: “This authorisation in the Republic of Korea is another encouraging and positive step in the development of Aivlosin as a fast growing, truly global brand.
“It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”
House broker Cenkos added that Korea is also a pig exporter (Japan, Philippines and Thailand) and so it is important to the economy that it has healthy livestock.
“This approval opens up a further important commercial market opportunity for Eco Animal Health.
“Since the placing last October, Eco Animal has delivered against a number of commercially important milestones, which is transforming Aivlosin into an important armament against infectious diseases in livestock worldwide in multiple species
Aivlosin has recently received marketing approvals for pigs and poultry across Europe, Russia, the US and Canada across a range of indications and species.
Cenkos maintained it ‘buy’ stance. Shares today were down slightly at 203p. Reported by Proactive Investors 1 hour ago.
ECO Animal Health (LON:EAH) has received first approval for its antibiotic Aivlosin in another key market as the South Korean authorities gave it the green light.
The marketing authorisation is for the use of a 42.5 mg/g premix and will be marketed for the treatment of diseases caused by Mycoplasma hyopneumoniae, one of the most important contributors to respiratory diseases in pigs.
A long standing relationship with a South Korean distributor had assisted in obtaining the marketing authorisation, said ECO.
Launch plans for Aivlosin in Korea are well advanced and is expected to take place within a couple of months, it said.
Pork is only second in importance to rice in South Korean agriculture with almost one million metric tons produced every year, with consumption increasing faster than any other type of meat.
Peter Lawrence, ECO Animal’s chairman said: “This authorisation in the Republic of Korea is another encouraging and positive step in the development of Aivlosin as a fast growing, truly global brand.
“It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.”
House broker Cenkos added that Korea is also a pig exporter (Japan, Philippines and Thailand) and so it is important to the economy that it has healthy livestock.
“This approval opens up a further important commercial market opportunity for Eco Animal Health.
“Since the placing last October, Eco Animal has delivered against a number of commercially important milestones, which is transforming Aivlosin into an important armament against infectious diseases in livestock worldwide in multiple species
Aivlosin has recently received marketing approvals for pigs and poultry across Europe, Russia, the US and Canada across a range of indications and species.
Cenkos maintained it ‘buy’ stance. Shares today were down slightly at 203p. Reported by Proactive Investors 1 hour ago.
